Business
AngioDynamics to Convene Cardiovascular Leaders at Scientific Forum as Pipeline Continues to Advance
Physician-led Collaboration Reinforces Ongoing Regulatory Activity and Clinical Advancement Across the Cardiovascular Portfolio LATHAM, N.Y.--(BUSINESS
About this update from Angiodynamics, Inc.
[{"type":"text","content":"\nPhysician-led Collaboration Reinforces Ongoing Regulatory Activity and Clinical Advancement Across the Cardiovascular Portfolio\n\n\n LATHAM, N.Y.--(BUSINESS WIRE)--\nAngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced it will convene leading cardiovascular physicians and researchers at its third Cardiovascular Scientific Forum, as the Company advances multiple cardiovascular programs following recent FDA regulatory milestones into active clinical engagement.\n\n\nThe Cardiovascular Scientific Forum is structured as a working scientific convening focused on physician-led collaboration, clinical evidence development, and the real-world application of emerging cardiovascular technologies. The program includes sessions on collaborative cardiovascular care, reimbursement and coding considerations, investigator-led research presentations, and hands-on thrombectomy and atherectomy workshops, along with focused discussions on venous thromboembolism, blood management, and peripheral arterial disease. Investigator meetings and focused working groups are intended to inform ongoing clinical studies and future research priorities across AngioDynamics’ cardiovascular portfolio.\n\n\nTaking place February 6–8, 2026, in Fort Lauderdale, Florida, the forum will bring together interventional cardiologists, surgeons, and clinical researchers to review emerging data, discuss study design and evidence priorities, and align on research pathways supporting the Company’s cardiovascular pipeline.\n\n\nThe scientific discussions and physician engagement at the Cardiovascular Scientific Forum are taking place against a backdrop of active regulatory and clinical progress across the Company’s cardiovascular portfolio. Recent FDA milestones and ongoing clinical study activity provide the foundation for the forum’s focus on evidence generation, procedural advancement, and investigator collaboration.\n\n\n“Innovation accelerates when the clinical community comes together around shared scientific priorities,” said Laura Piccinini, Senior Vice President and General Manager, Cardiovascular & International at AngioDynamics. “This forum reflects our commitment to rigorous, evidence-based col...